Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Buprenorphine Header

    Virtual Booth

    Contact Supplier

    Buprenorphine

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SCI PHARMTECH Buprenorphine

    Virtual Booth

    Contact Supplier

    Buprenorphine

    Virtual Booth

    Contact Supplier

    Menu

    Buprenorphine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,328Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alar Announces ALA-1000's Efficacy, Safety in Canine OA Study
    Alar Announces ALA-1000's Efficacy, Safety in Canine OA Study

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alar-announced-buprenorphine-injectable-ala-1000-demonstrated-long-term-efficacy-and-favorable-safety-profile-in-canine-osteoarthritis-pain-management-302713151.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    Monthly Injectable Buprenorphine Cuts Costs in Opioid Disorder
    Monthly Injectable Buprenorphine Cuts Costs in Opioid Disorder

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253803/0/en/New-Study-Shows-Adherence-to-Monthly-Injectable-Buprenorphine-Linked-to-Lower-Healthcare-Utilization-and-Costs-in-Opioid-Use-Disorder.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Io Therapeutics Announces Studies On IRX4204 For Breast Cancer
    Io Therapeutics Announces Studies On IRX4204 For Breast Cancer

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3253966/0/en/Io-Therapeutics-Inc-announces-publication-of-studies-on-the-company-s-RXR-agonist-compound-IRX4204-for-breast-cancer-prevention.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Dexcel Pharma USA Acquires US Rights To Zubsolv
    Dexcel Pharma USA Acquires US Rights To Zubsolv

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dexcel-pharma-usa-acquires-us-rights-to-zubsolv-302655715.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Study: Extended-Release Buprenorphine Safely Reduces Opioid Use
    Study: Extended-Release Buprenorphine Safely Reduces Opioid Use

    17 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-study-shows-extended-release-buprenorphine-safely-delivers-rapid-clinically-meaningful-reductions-in-opioid-use-and-supports-abstinence-in-high-risk-populations-302644924.html

    PR NEWSWIRE
    17 Dec 2025
    Share Share
    Purdue Expands Low-Cost Opioid Disorder Treatment to Prisons
    Purdue Expands Low-Cost Opioid Disorder Treatment to Prisons

    02 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250902734627/en/Purdue-Pharma-L.P.-Expands-its-Provision-of-Low-Cost-Opioid-Use-Disorder-Treatment-to-Correctional-Facilities-for-Incarcerated-Individuals

    BUSINESSWIRE
    02 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.